CLINICO-BIOLOGIC AL DEMENTELOR Prof. Dr. Ovidiu Bajenaru
UMF Carol Davila Bucuresti Spitalul Universitar de Urgenta Bucuresti Clinica de Neurologie Dementele provocarea viitorului Numrul persoanelor cu vrst peste 65 de ani se va dubla pn n 2030 1 Numrul persoanelor suferind de boala Alzheimer se va dubla pn n 2050* Estimare a numrului de persoane suferind de dementa, 2005-2050* P e r s o a n e
s u f e r i n d
d e
b o a l a
A l z h e i m e r
( m i l i o a n e )
An 1. Green Paper on Demographic change, Brussels 2005;12(suppl 1):1-27 *Sursa: Datamonitor, publicat Martie 2008 Lim, et al. J Am Geriatr Soc. 1999 May;47(5):564-9 DEMENTA reprezinta un sindrom clinic neurolgic caracterizat printr-o deteriorare cognitiva globala, care implica un declin fata de nivelul anterior de functionare si care asociaza o gama larga de simptome psihice, psihologice si comportamentale. Tulburarile functiilor cognitive sunt uneori precedate si aproape ntotdeauna nsotite de:
- tulburari ale controlului emotional - modificari ale personalitatii - alte simptome psihiatrice: * apatie, depresie, tulburari psihotice * tulburari comportamentale ETIOLOGIE dementele = un grup heterogen de afectiuni neurologice primare sau secundare asociate unor boli sistemice cu afectare a sistemului nervos central
formele cele mai ntlnite: - dementa din boala Alzheimer - dementele vasculare - dementa din -sinucleinopatii * dementele cu corpi Lewy * dementa asociata bolii Parkinson - formele mixte * boala Alzheimer asociata cu boala cerebro-vasculara * boala Alzheimer asociata cu dementa cu corpi Lewy - dementele fronto-temporale I. Boli in care dementa este asociata cu semne clinice si de laborator ale altor afectiuni medicale:
A. Infectia HIV / SIDA B. Afectiuni endocrine: hipotiroidism, sd. Cushing, hipopituitarism C. Carente nutritionale: sd. Wernicke-Korsakov, degenerescenta combinata subacuta ( carenta de vit. B12 ), pelagra D. Meningoencefalite cronice: paralizia generala progresiva, sifilisul meningo-vascular, criptococcoza E. Degenerescenta hepato- lenticulara familiala ( b. Wilson ) si dobandita F. Intoxicatii cronice ( inclusiv statusul dupa intoxicatie cu CO ) G. Hipoglicemia sau hipoxia prelungita H. Encefalita limbica paraneoplazica I. Expunera la metale grele: As, Bi, Au, Mn, Hg J. Dementa dialitica ( rara in prezent, datorita evolutiei tehnologiilor de dializa ) Pacienta cu sd. demential encefalita limbica paraneoplazica asociata cu adenocarcinom pulmonar: debut neurologic inainte de diagnosticul oncologic
II. Boli in care dementa este asociata cu alte semne neurologice, dar fara alte afectiuni medicale evidente(1):
A. Invariabil asociate cu alte semne neurologice: 1. Boala Huntington 2. Scleroza multipla, boala Schilder, adreno-leucodistrofia si alte boli inrudite care afecteaza mielina SNC 3. Lipidozele 4. Epilepsia mioclonica 5. B. Creutzfeldt- Jacob ( clasica si noua varianta ) b.Gerstmann-Strausler-Scheinker (dementele mioclonice, prionice) 6. Degenerescenta cerebro-cerebeloasa 7. Degenerescentele cortico-bazale DFT 8. Dementa cu paraplegie spastica 9. Paralizia supranucleara progresiva ( PSP ) DFT 10. Boala Parkinson 11. Boala difuza cu corpi Lewy 12. Scleroza laterala amiotrofica & dementaDFT 13. Complexul Parkinson-SLA-dementa 14. Alte boli metabolice ereditare rare
II. Boli in care dementa este asociata cu alte semne neurologice, dar fara alte afectiuni medicale evidente (2):
B. Adesea asociate cu alte semne neurologice: 1. AVC multiple ( ischemice/ hemoragice ) si b. Binswanger 2. Tumorile ( primare/ secundare ) sau abcesele cerebrale* 3a. Hematoamele intracraniene cronice* 3b. Leziuni dupa traumatisme cranio-cerebrale ( de regula tipuri de leziuni insotite de diferite forme de sangerare cerebrala ) 4. Boala difuza cu corpi Lewy 5. Hidrocefaliile comunicante normotensive sau hidrocefaliile obstructive* 6. Leucoencefalita multifocala progresiva ( LEMP ) 7. Boala Marchiafava Bignami 8. Granulomatozele si vasculitele cerebrale 9. Encefalitele virale III. Boli in care de obicei dementa este singura manifestare evidenta a unei afectiuni neurologice sau medicale:
A. Boala Alzheimer B. Unele cazuri de SIDA C. Dementele fronto-temporale ( inclusiv sd. afazice primare progresive) si cele de lob frontal F. Boli degenerative nespecificate CRITERII DE DIAGNOSTIC DSM IV TR ( nu mai este de actualitate, incepand cu mai 2013): Criteriile diagnosticului de demen, indiferent de cauza:
1. Dezvoltarea mai multor deficite cognitive, dintre care obligatoriu: Afectarea memoriei (scderea capacitii de a nva informaii noi sau de a evoca informaii nvate anterior)
si,
Cel puin una dintre urmtoarele:
Afazie (tulburare de limbaj) Apraxie (afectarea abilitii de a executa activiti motorii ntr-o anume secven i care servesc unui scop, n lipsa afectrii funciei motorii) Agnozie (incapacitatea de a recunoate sau identifica obiecte n lipsa afectrii funciilor senzoriale) Perturbarea funcionrii excutive (planificare, organizare, secvenializare, abstractizare). CRITERII DE DIAGNOSTIC 2. Deficitele cognitive menionate mai sus reprezint un declin fa de nivelul anterior de funcionare i cauzeaz, fiecare, afectarea semnificativ a funcionrii sociale sau ocupaionale
3. Deficitele cognitive menionate mai sus nu apar exclusiv n cursul unui episod de delirium
4. Criterii de diagnostic specifice se adaug pentru stabilirea diferitelor etiologii ale demenei
5. Afectarea memoriei trebuie obligatoriu s fie prezent ns uneori poate s nu fie simptomul predominant ( f-ctie de forma etiopatogenica ! ) va disparea in DSM5
6. Pentru a se putea stabili diagnosticul de demen, deliriumul* i orice alt tip de tulburare confuzional trebuie exclus prin diagnostic diferenial. NEUROCOGNITIVE DISORDERS A proposal from the DSM-5 Neurocognitive Disorders Work Group Neurocognitive Disorders - a new category to replace the DSM-IV Category of Delirium, Dementia, Amnestic, and Other Geriatric Cognitive Disorders
The defining characteristics of these disorders are that their core or primary deficits are in cognition and that these deficits represent a decline from a previously attained level of cognitive functioning
This section includes three broadly defined syndromes: (1) Delirium (2) Major Neurocognitive Disorder (3) Mild Neurocognitive Disorder Neurocognitive Disorder - new reccomended criteria by APA - Terminology for the cognitive domains has been updated to reflect current usage in neuropsychology and neurology
Evidence of significant cognitive decline from a previous level of performance in one or more of the domains based on: Complex attention (sustained attention, divided attention, selective attention, processing speed) Executive ability (planning, decision-making, working memory, responding to feedback/error correction, overriding habits, mental flexibility) Learning and memory (immediate memory, recent memory [including free recall, cued recall, and recognition memory]) Language (expressive language [including naming, fluency, grammar and syntax] and receptive language) Visuoconstructional-perceptual ability (construction and visual perception) Social cognition (recognition of emotions, theory of mind, behavioral regulation)
Major Neurocognitive Disorder A. Evidence of significant cognitive decline from a previous level of performance in one or more of the domains outlined above based on:
1. Concerns of the patient, a knowledgeable informant or the clinician that there has been a significant decline in cognitive function AND 2. Clear decline in neurocognitive performance, typically 2 or more standard deviations below appropriate norms on formal testing, or equivalent clinical evaluation.
B. The cognitive deficits are sufficient to interfere with independence (i.e., requiring assistance at a minimum with instrumental ADL [more complex tasks such as paying bills or managing medications]).
C. The cognitive deficits do not occur exclusively in the context of a delirium.
D. The cognitive deficits are not wholly or primarily attributable to another Axis I disorder (e.g., Major Depressive Disorder, Schizophrenia)
Mild Neurocognitive Disorder A. Evidence of minor cognitive decline from a previous level of performance in one or more of the domains outlined above based on: 1. Concerns of the patient, a knowledgeable informant or the clinician that there has been a mild decline in cognitive function AND 2. Mild decline in neurocognitive performance, typically between 1 and 2 standard deviations below appropriate norms on formal testing, or equivalent clinical evaluation.
B. The cognitive deficits are insufficient to interfere with independence (i.e., instrumental ADL [more complex tasks such as paying bills or managing medications] are preserved), but greater effort, compensatory strategies, or accommodation may be required to maintain independence.
C. The cognitive deficits do not occur exclusively in the context of a delirium.
D. The cognitive deficits are not wholly or primarily attributable to another Axis I disorder (e.g., Major Depressive Disorder, Schizophrenia). The distinction between Major and Mild disorders is primarily one of severity, with the threshold for Major Neurocognitive Disorder encompassing a greater degree of cognitive impairment and hence a loss of independence in instrumental activities of daily living
In most progressive disorders such as the neurodegenerative disorders and some forms of vascular cognitive impairment, Minor and Major may be earlier and later stages of the same disorder S 24 - 35 Major Neurocognitive Disorder S 24 Major Neurocognitive Disorder S 25 Major Neurocognitive Disorder Associated with Alzheimer's Disease S 26 Major Neurocognitive Disorder Associated with Vascular Disease S27 Major Neurocognitive Disorder Associated with Fronto-Temporal Lobar Degeneration S 28 Major Neurocogntive Disorder Associated with Traumatic Brain Injury S 29 Major Neurocognitive Disorder Associated with Lewy Body Disease S 30 Major Neurocognitive Disorder Associated with Parkinson's Disease S 31 Major Neurocognitive Disorder Associated with HIV Infection S 32 Major Neurocognitive Disorder Associated with Substance Use S 33 Major Neurocognitive Disorder Associated with Huntington's Disease S 34 Major Neurocognitive Disorder Associated with Prion Disease S 35 Other Specified Major Neurocogntive Disorder S 12 - 23 Mild Neurocognitive Disorder S 12 Mild Neurocognitive Disorder S 13 Mild Neurocognitive Disorder Associated with Alzheimer's Disease S 14 Mild Neurocognitive Disorder Associated with Vascular Disease S 15 Mild Neurocognitive Disorder Associated with Fronto-Temporal Lobar Degeneration S 16 Mild Neurocognitive Disorder Associated with Traumatic Brain Injury S 17 Mild Neurocognitive Disorder Associated with Lewy Body Disease S 18 Mild Neurocognitive Disorder Associated with Parkinson's Disease S 19 Mild Neurocognitive Disorder Associated with HIV Infection S 20 Mild Neurocognitive Disorder Associated with Substance Use S 21 Mild Neurocognitive Disorder Associated with Huntington's Disease S 22 Mild Neurocognitive Disorder Associated with Prion Disease S 23 Other Specified Mild Neurocogntive Disorder DSM-5 Neurocognitive Criteria, Draft 1/7/10 M E M O R I A
DECLARATIVA ( EXPLICITA ) NON-DECLARATIVA / PROCEDURALA ( IMPLICITA ) Fapte Evenimente COMPORTAMENTALA (abilitati, obiceiuri) De IDENTIFICARE (DETECTARE) De INVATARE ASOCIATIVA DE BAZA De INVATARE NON-ASOCIATIVA RASPUNSURI EMOTIONALE RASPUNS MUSCULAR SCHELETIC HIPOCAMP LOB T MEDIAL DIENCEFAL STRIAT CORTEX MOTOR CEREBEL NEOCORTEX SISTEM LIMBIC CEREBEL CAI REFLEXE MILD COGNITIVE IMPAIRMENT ( MCI )
Criterii clinice pentru MCI: ( Mayo Alzheimer Disease Center, Petersen et al., 1999, modificate in 2001 )
1. Acuze privind tulburari cognitive (de obicei de memorie), de preferat sesizate si de o persoana din anturaj
2. Tulburari cognitive (de obicei de memorie) obiective, in raport cu varsta si nivelul de instruire
3. Functiile cognitive generale intacte in cea mai mare masura
4. Conservarea in esenta a activitatilor din viata cotidiana
5. Absenta dementei
B. Alzheimer Depresie B. Alzheimer VaD Depresie DFT DLB VaD Domeniu unic Domenii multiple Domeniu unic Domenii multiple MCI amnestic a MCI non-amnestica C l a s i f i c a r e
c l i n i c a
SUBTIPURI de MCI Degenerativa Vasculara Psihiatrica Conditii medicale ETIOLOGIE
Examenul clinic general - obligatoriu - semne care s orienteze ctre diagnosticul unei afeciuni generale care se nsoete de demen ( tumor malign, afeciune metabolic, SIDA, hipotiroidism, anemie sever, etc.)
Examenul neurologic obligatoriu - poate decela semne neurologice specifice care s orienteze diagnosticul ctre boli neurologice primare care se asociaz cu demen (boala Wilson, boala Creutzfeldt-Jacob, etc.).
* Ex. : examenul neurologic este foarte important pentru a deosebi o demen de tip Alzheimer de o demen vascular.
- se recomand: ionograma investigarea funciei tiroidiene nivelul seric de vitamin B12
- pot fi necesare analize specifice: * teste serologice pentru boli infecioase ( HIV, sifilis, borelioz, encefalita herpetic, etc.) * teste imunologice (diagnosticul vasculitelor, a lupusului sistemic, etc.) * probe toxicologice (intoxicaii cu metale grele) * teste genetice (identificarea bolii Alzheimer precoce familiale, DFT, CADASIL, etc.) * alte determinari (ex. homocistein) * alte teste specifice
Examenul lichidului cefalorahidian
- n cazuri selecionate de diagnostic diferenial
- in boala Alzheimer: * peptidul A42 are un nivel sczut * proteina tau & proteina tau fosforilata - nivel crescut vs. non-demeni de aceeai vrst ( grad de recomandare de nivel B )
- in cazul suspiciunii de boal Creutzfeldt-Jakob: * proteina 14-3-3 este important pentru diagnostic ( grad de recomandare de nivel B )
Investigaiile neuroimagistice
- Rolul principal: * excluderea alte patologii cerebrale * sprijinirea diagnosticul tipului de demen neurodegenerativ n boala Alzheimer, atrofia cerebral predominant la nivelul hipocampului i a lobului T n DFT atrofia cerebral predominant la nivelul lobilor F i T n demena vascular: evidenierea leziunilor vasculare i a tipului acestora, etc.
NB. Sunt ns i situaii n care simptomatologia este clinic evident pentru boala Alzheimer dar CT-ul nu este modificat pentru vrsta pacientului.
Investigaiile neuroimgistice nu sunt absolut necesare pentru diagnosticul bolii Alzheimer efectuat ntr-un stadiu deja avansat al bolii, cu manifestri clinice severe.
Investigaiile neuroimagistice
- ajuta la stabilirea diagnosticului de demen
- cel putin CT cerebrala fr contrast (grad de recomandare de nivel A)
- in cazuri selecionate:IRM cerebral (grad de recomandare de nivel A) sau examinri imagistice cu contrast
- in cazuri selecionate: SPECT cerebrala * diagnosticul etiologic al demenei * diagnostic diferenial: demen Alzheimer i demen vascular (grad de recomandare de nivel B)
- PET cu PIB ( Pittsburg Compound B ): gradul de incarcare cerebrala cu amiloid: d. Alzheimer, DLB vs PD-D
Forsberg A, et al. Neurobiol Aging 2008; 29: 14561465. PET cu PIB ( Pittsburg Compound B )
PDD: incarcare mica cu amiloid DLB: incarcare semnificativa cu amiloid !
Examenul electroencefalografic (EEG) poate fi necesar uneori ( grad de recomandare de nivel B )
- n cazuri selecionate (spre exemplu n suspiciunea de CJD sau de encefalite)
Biopsia cerebral - necesar numai n cazuri rare, selecionate cu mare grij, n care diagnosticul etiologic nu poate fi stabilit prin alte proceduri
- n centre de neurochirurgie cu experien
- numai la recomandarea neurologului sau psihiatrului curant si - cu acordul scris al familiei sau reprezentantului legal al bolnavului.
- pt. b. Alzheimer: substituita astazi de markerii biologici in LCR
BOALA ALZHEIMER - cea mai frecventa boala neurodegenerativa, 2/3 dintre demente - 10% peste 60 ani, 1 din 3 peste 85 ani
MODIFICARI GENETICE CUNOSCUTE: - gena APP de pe cromozomul 21
- PS 1 de pe cromozomul 14 ( proteina S 182 ): > 40 mutatii (clivaj al APP in situsul pt.-secretaza ); 40 70% dintre bolnavii cu b. Alzheimer cu debut precoce si evolutie mai rapida: 6 7 ani ( forma mai rara )
- PS 2 de pe cromozomul 1 ( STM 2 ): debut mai tardiv si evolutie mai lunga ( 11 ani ) * PS rareori implicate in formele cele mai comune, sporadice
- gena ApoE de pe cromozomul 19 (formele sporadice comune) alelele c4: asociere cu b. Alzheimer ( homozigotia c4=f.risc) * relatie cu transportul colesterolului Bogdanovic & Winblad, Huddinge Brain Bank, 2006 Intracellular Hyperphosphorylated tau
- Neurofibrillary tangles - Senile plaques Extracellular Amyloid -peptide (A) AD Neuropathology - Neuronal and Synaptic loss - Inflammatory response - Vascular lesions Boller F. et al - Cortex, (2007) 43, 565-569 Marinesco G, tude anatomique et clinique des plaques dites sniles, Encphale (Paris), 1er semestre, 1912, 105132. Blocq P, Marinesco G, Sur les lsions et la pathologie de lpilepsie dite essentielle, La Semaine mdicale, novembre 1892, 445446 (travail du laboratoire du Pr Charcot).
Marinesco G, Nouvelles recherches sur les plaques sniles (1928). In: ***, OEuvres choisies (1963), vol. II, Masson, Paris, 1897, 133. Continutul unei placi amiloide
Nucleu de amiloid, inconjurat de leziuni degenerative - in placa exista si alte substante: apoE
Cu timpul, neuronii din jur degenereaza si acumuleaza proteina tau
hiperfosforilata Procesarea APP
modificat dupa Querfurth H and LaFerla F.- N Engl J Med 2010;362:329-344 Zheng and Koo Molecular Neurodegeneration 2011 6:27 doi:10.1186/1750-1326-6-27
Zheng and Koo Molecular Neurodegeneration 2011 6:27 doi:10.1186/1750-1326-6-27 Spuch C.,Ortolano S.,Navarro C. - J ournal of Aging Research Volume 2012, Article ID 324968, doi:10.1155/2012/324968
Ipoteza cascadei amiloide Degenerescente neurofibrilare Placi amiloide Creste productia si scade clearence-ul, A 42 Placi difuze A 40 Tau PHF-tau Activitatea kinazelor si fosfatezelor e alterata Stress oxidativ Tulburari [Ca ++ ] Inflamatie cronica Toxicitate glutamatergica Apoptoza Deteriorare structurala Disfunctie si moarte neuronala
Dementa oligomerizarea si depunerea A 42 Depozite A Gene Factori de mediu Hiperfosforilarea tau & NFT Microtubulii = parti din citoscheletul neuronal - formati din subunitati de tubulina (proteina) stabilizata de: - 2 proteine unice asociata microtubulilor (MAP) * proteina tau = una din aceste proteine Tau = MAP ce stabilizeaza microtubulii in configuratia neuronala normala - permite transportul axonal normal al factorilor nutritivi si altor molecule in interiorul neuronului Hiperfosforilarea tau * destabilizarea microtubulilor, * agregarea proteinei tau / formarea NFT t moarte neuronala
FOSFORILAREA SI DEFOSFORILAREA PROTEINEI TAU Querfurth HW, LaFerla FM. NEJ M 2010 Degenerescentele neurofibrilare - NFT Degenerescentele neurofibrilare intraneuronale sunt compuse din filamente helicoidale in perechi, derivate din agregate de proteina tau produse prin procesul de hiperfosforilare
A and BBB Brain Capillary A| LRP- 1 RAG E LRP-1 = low density lypoprotein receptor-related protein RAGE = receptor for advanced glycation end-products Drawing following the concept of Deane et al., Nature Med, 2003 A| in: -blood -vessels (CAA) -brain tissue
Axa ficat creier
Insulina plasmatica faciliteaza clearance-ul hepatic al amiloidului plasmatic (1-40) prin translocarea intracelulara a LDL Receptor-related Protein-1 ( LRP-1) catre membrana plasmatica a hepatocitelor
Previne acumularea cerebrala a A ( 1-40)
DZ tip 2 & MetSy ( REZISTENTA CRESCUTA la INSULINA )
FACTORI DE RISC pentru BA
Tamaki C. et al, Molecular Pharm, 2007
In Alzheimer disease and CAA, accumulation of A in the media of cortical arterioles weakens the vessel wall and increases the chance of lobar hemorrhages The major risk factors for VCI and Alzheimer disease hypertension, aging, and diabetes impair endothelium-dependent responses in the cerebral microcirculation and blunt functional hyperemia A is a potent vasoconstrictor and suppresses endothelium-dependent responses, functional hyperemia, and cerebrovascular autoregulation. Cerebral smooth muscle cells of patients with Alzheimer disease have increased constrictor tone, which may contribute to the CBF reduction observed in this condition. Vascular oxidative stress and inflammation are key pathogenic factors in neurovascular dysfunction Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias The combination between cerebrovascular lesions and Alzheimer-type pathology is the most common neuropathological finding in elderly patients with dementia.
More than 77% of subjects with Alzheimer's disease had grossly apparent circle of Willis atherosclerosis, a percentage that was significantly higher than normal (47%), or other neurodegenerative diseases (43-67%). Age- and sex-adjusted atherosclerosis ratings were highly correlated with neuritic plaque, paired helical filaments tau neurofibrillary tangle and cerebral amyloid angiopathy ratings in the whole sample and within individual groups.
These results provide further confirmation and specificity that vascular disease and Alzheimer's disease are interrelated and suggest that common aetiologic or reciprocally synergistic pathophysiological mechanisms promote both vascular pathology and plaque and tangle pathology
Increased cardiovascular risk was associated with reduced gray matter volume and thickness in regions also affected by Alzheimer disease independent of infarcts and apolipoprotein E genotype. These results suggest a "double hit" toward developing dementia when someone with incipient Alzheimer disease also has high cardiovascular risk
Yarchoan M et al - Brain. 2012 Nov 30. [Epub ahead of print] Cardenas VA et al - Stroke. 2012 Nov;43(11):2865-70 Diehl J , Kurz A. - Fortschr Neurol Psychiatr.2002;70(3):145-54
February 2011 The Alzheimers Disease puzzle The AD Network Puzzle Cedazo-Minguez JCMM 2008 Hypercholesterolemia However: NORMAL Ch is essential for many physiologic processes modulates fluidity of cell membranes & is essential for basic synaptic integrity and neurotransmission All these processes - are compromised with aging - have been shown to be dysfunctional in AD
N Ch could have a protective effect in patients with AD ! Mielke MM et al, Neurology, 2005
HIGH MIDLIFE serum Ch is a RF for subsequent dementia/ AD
but spontaneously decreasing serum Ch after midlife reflect ongoing disease processes and may represent a risk marker for late-life cognitive impairment (21 y follow-up of 1449 individuals )
Solomon A. et al. Neurology 2007 Ltjohann D et al - Clin Lipidology. 2012;7(1):65-78 Pathophysiological Processes Leading to DEMENTIA Possible Targets for Therapy Aging Neurotransmitters deficits Micro- & astroglia activation Inflammation Cognitive dysfunction Oxidative stress Disbalance: calcium
energy antioxidant triangle APP & presenilin mutations (AD) Increased A| production Tau protein hyperphosphorilation Synaptic damage Neurodegeneration Neuronal death Current approaches to drug therapy Future treatment strategies VASCULAR (VAD, AD) Accumulation of peptides (A, -synuclein) DLB degradation (proteasomal) deficit? Tau mutations (FTD) Human and experimental animal studies revealed that neurodegeneration associated with peripheral insulin resistance is likely effectuated via a liver-brain axis whereby toxic lipids, including ceramides, cross the blood brain barrier and cause brain insulin resistance, oxidative stress, neuro-inflammation, and cell death.
In essence, there are dual mechanisms of brain insulin resistance leading to AD-type neurodegeneration: one mediated by endogenous, CNS factors; the other: peripheral insulin resistance with excess cytotoxic ceramide production.
[BMB reports 2009; 42(8): 475-481]
del Monte SM, 2009 REZISTENTA LA INSULINA IN BOALA ALZHEIMER
Studii epidemiologice: asociere semnificativa a dementelor din boala Alzheimer si posibil a dementelor vasculare, cu:
diabetul zaharat sd. metabolic
Craft S et al - Arch Gen Psychiatry 1999; 56: 1135-1140; Kern W et al - Neuroendocrinology 2001; 74: 270-280; Craft S et al - Neuroendocrinology 1999; 70: 146-152.
FIZIOLOGIC: - Insulina ( via GSK 3 ) inhiba HIPERFOSFORILAREA PROTEINEI TAU
inhiba formarea degenerescentelor neuro-fibrilare
- Rezistenta crescuta la insulina ~ accelereaza formarea placilor neuritice ( crescuta suplimentar la purtatorii APOE 4 )
HIPERINSULINISMUL CRONIC: insulina exacerbeaza raspunsul inflamator cronic si creste stress-ul oxidativ ( posibil rol: ceramidele rezultate din alterarea metabolismului lipidic periferic ( axa ficat creier trec BHE efecte neurotoxice si proinflamatorii prin citokine pro-inflamatorii )
inflamatia: promotor al patogeniei b.A. Facchini FS, Hua NW, Reaven GM, Stoohs RA. - Free Radic Biol Med 2000; 29: 1302-1306; Axelrod L. - Diabetes 1991; 40: 1223-1227; Laight D, Desai K, Gopul N - Eur J Pharmacol 1999; 377: 89-92; Soop M, Duxbury H, Agwunobi A - Am J Physiol Endocrinol Metab 2002; 282: E1276-E1285; del Monte SM - BMB reports 2009; 42(8): 475-481; Matsuzaki T - Neurology, 2010, 75 ( 9 ): 764-770 TNF inhiba clearance-ul A Insulina previne acumularea A intracelular facilitand eliberarea sa Insulina & IGF-1 faciliteaza intrarea crescuta in SNC a proteinelor de transport ( albumina & transthyretine ) legarea A transportul A catre LCR si sange
TNF inhiba IRS reduce trecerea proteinelor de transport in SNC Gasparini L, Xu H - Trends Neurosci 2003; 26: 404-406; White MF - Am J Physiol Endocrinol Metab 2002, 283:E413E422
METABOLIC SYNDROME LIFESTYLE GENETICS ? ATYPIC ANTIPSYCHOTICS OSHAS CHRONIC SLEEP DEPRIVATION STROKE CHD COGNITIVE IMPAIRMENT/ / DEMENTIA ( AD ) VASCULAR DEATH BRAIN (Metabolic control) Epidemiological findings of vascular risk factors in Alzheimer's disease: implications for therapeutic and preventive intervention Systematic reviews and meta-analyses of population-based prospective studies have concluded from the life-course perspective (supported by population-based neuroimaging and neuropathological studies ) an age-dependent association with the risk of AD for several vascular factors, such as : high blood pressure obesity high total cholesterol Possessing these factors in midlife is associated with an increased risk of late-life AD, whereas having a low level in late life or a decline after middle age in these factors may anticipate clinical onset of AD
Practicing clinicians can reasonably state to patients that, although more definitive research is clearly needed, the management and treatment of vascular disease risk factors are likely beneficial not only to prevent heart disease and stroke, but also common forms of dementia in the community
Romn GC, Nash DT, Fillit H - Alzheimer Dis Assoc Disord. 2012 Oct;26(4):295-9 Alzheimer's disease is a pathological diagnosis using a series of standardised criteria
Alzheimer's dementia is a clinical syndrome that is possibly or probably as a consequence of Alzheimer's disease ( progressive neurodegenerative disease ) Alzheimer's dementia is most commonly defined in a research setting using the NINCDS-ADRDA criteria which compared to results at autopsy, detects Alzheimer's disease with a sensitivity of 9198%
Years before the onset of clinical symptoms of demential syndrome, there is an AD process evolving along a predictable pattern of progression in the brain
Braak H, Braak E. - Acta Neuropathol (Berl), 1991; Delacourte A et al. Neurology, 1999 Dubois B. et al, Lancet Neurology, 2007
Frisoni GB, et al. Nat Rev Neurol 2010; 6: 6777 Is it possible to diagnose Alzheimers disease during the predementia stage ? Forsberg A, et al. Neurobiol Aging 2008; 29: 14561465. BOALA ALZHEIMER
MANIFESTARI CLINICE * boala neurologica progresiva cu pierdere ireversibila de sinapse si neuroni, predominent corticala (hipocamp si neocortex ) - elementele clinice esentiale ( in stadiul demential ): * afectarea progresiva a memoriei, judecatii, a capacitatii de decizie * afectarea capacitatii de orientare in mediul fizic * afectarea limbajului
ELEMENTE NEUROPATOLOGICE ESENTIALE: * pierderea sinaptica si neuronala * placile senile extracelulare ( care contin |-amiloid ) * degenerescentele neurofibrilare ( NFT ) ( cu proteina tau microtubulara hiperfosforilata )
MANIFESTARI CLINICE - semnele precoce sunt subtile, adesea ignorate: * lipsa de initiativa, scaderea interesului fata de activitatile profesionale, neglijarea sarcinilor de rutina, disparitia interesului fata de activitatile care faceau placere ("oboseala"); sau, * instabilitate emotionala, tulburari afective ( depresie, cel mai frecvent ), apatie ( rareori exaltare nejustificata ), fluctuatii nejustificate ( ras plans ).
- progresiv, dezvoltare graduala a tulburarilor mnezice ( nume proprii, intalniri fixate, conversatii recente, evenimente sociale, repeta aceleasi intrebari uitand raspunsurile); - distractibilitate usoara determinata de orice eveniment trecator; - conversatia pierde din claritate, nu mai intelege toate nuantele si aspectele conversatiei, unei situatii; - preocupare excesiva pt. aspecte neimportante; - sarcini care implica mai multi timpi nu mai pot fi realizate; - apar dezorientari, chiar in mediul obisnuit ( mai tarziu rataciri); - acuze somatice: ameteli, neclaritate mentala, cefalee nesistematizata; - uneori stare confuzionala acuta determinata de o boala febrila, un traumatism, o operatie, un nou medicament, schimbarea mediului obisnuit, etc.
- mai tarziu: * pierderea abilitatilor sociale si interferenta cu obiceiurile sociale; * alterarea judecatii; * suspiciozitate crescuta, manifestari paranoiace; * alterare severa antero / retrograda a memoriei ( nu mai recunoaste rudele apropiate, numele copiilor, etc.); * apraxii si agnozii interfera cu realizarea unor sarcini simple; - afectarea limbajului: * in unele demente ( altele decat AD, in particular FTD ): de la inceput * pierderea intelegerii nuantelor de limbaj ( vorbit, scris ); * restrangerea vocabularului, vorbire cu repetitii * nu se mai exprima in fraze si propozitii lungi, bine constituite * tendinta de folosi formule verbale stereotipe, exclamatii * parafazii, dificultate de a intelege fraze complexe * agravare in timp palilalie, echolalie, nu-si mai pot exprima verbal sentimentele concomitent cu degradare comportamentala, etc. - nu mai pot face calcule, nu mai recunosc ceasul
- in stadii avansate pot ramane ambulatori, dar se deplaseaza fara un scop; au complet pierdute abilitatile cognitive, ratiunea, judecata; pierderea inhibitiei, comportament agresiv, beligerant alternand cu pasivitate si retragere sociala - perturbarea ritmului veghe-somn, cu inversiune, adesea cu agitatie psiho-motorie vesperala ( " sun-down syndrome" ); - tulburari de mers, cu nesiguranta si rigiditate musculara generalizata asociata cu lentoare si lipsa de spontaneitate a miscarilor ( ~ parkinsonism ! );
- in stadiile finale: * rigiditate, mutism, incontinenta, imobilizati la pat ( frecvent, dar nu obligatoriu ) * necesita ajutor pentru cele mai elementare sarcini ( hranire, imbracat, toaleta, etc ) * ROT exagerate, dezinhibitia unor reflexe ancestrale ( r. Toulouse, supt, s.a. ) * tresariri mioclonice la stimuli senzitivi, auditivi ( A CJD ) * crize epileptice generalizate ( posibile )
- deces: tulburari de nutritie, infectii, IMA
DURATA MEDIE TIPICA: 8 10 ani ( extreme: 1 25 ani! ) Progress of Symptom Development Time Mobility Behaviour Cognitive function Mood Gauthier (1999); Feldman, Kertesz (2001); Auer et al. (1996); Reisberg et al. (1996); Barclay et al.(1985) D e t e r i o r a t i o n
Factori de risc si de protectie in patogenia bolii Alzheimer modificat dupa Arrizaga R. Congres SSNN, Cracovia 2011 Roe CM et al. Neurology 2011; 76:501-510 FACTORI DE RISC in BA Genetici Varsta Vasculari HTA H-colesterolemie H-trigliceridemie Diabetul zaharat Sd. metabolic AVC Homocisteinemia Fumatul BMI Depresia
FACTORI DE PROTECTIE in BA Genetici Educatia Stilul de viata Dieta Activitatea cerebrala Activitatea fizica Interventii farmacologice Anti-HTA Statine preventia primara & secundara a AVC AINS ? Estrogeni ?! REZERVA - COGNITIVA - CEREBRALA ( structurala ) FACTORI DE RISC
Diabetul zaharat asociat cu ApoE4 creste > x 2 riscul b. Alzheimer ( |nr. placi amiloide & NFT, probabil si prin intermediul bcv ) New approach of AD and VaD
VaD AD with/ CVD CVD is the pathology; VaD is the clinical disease VaD without AD pathology is relatively rare Most patients have significant overlap between AD and CVD This overlap is AD w/CVD AD Risk factors and markers in Dementia: Continuum between AD and VaD Definite AD Probable AD Possible AD Possible VaD Probable VaD AD + CVD Definite VaD Hypertension Stroke/TIA Hypercholesterolemia Heart Disease Hypercholesterole mia Amyloid Plaques Genetic s AD VaD Neurofibrillary Tangles Diabetes Kalaria RN, Ballard C. Alzheimer Dis Assoc Disord. 1999;13:S115-123 Hypertension Cholinergic deficits Brain Infarcts LESIONS in ALZHEIMERs DISEASE and VASCULAR DEMENTIA (Kalaria R.N., 2001)
Relationship among AD, VaD and other dementias AD VaD Other (PDD, DLBD,FTD, etc. ) Cras, 1998 Processes influencing clinical expression of dementia Additional opportunities for interventions
Sperling RA et al - Alzheimer's & Dementia: The J ournal of the Alzheimer's Association 2011, 7 (3): 280-292 MODIFICARI IN NEUROTRANSMISIE: ( fenomene secundare leziunilor neuronale )
- afectare predominenta a sistemului colinergic * diminuare marcata a ACh, CAT, receptori nicotinici * diminuarea ChE, cresterea BuChE ( asociata placilor senile si NFT ) degenerescenta nc. basalis Meynert Baza terapiei simptomatice cu ChEI: - donepezil - rivastigmine - galantamine - reducere a activitatii sistemului noradrenergic
- sistemul glutamatergic (nivel crescut de glutamat) Baza terapiei simptomatice cu ANTAGONISTI PARTIALI rNMDA: - memantine
TRATAMENT SIMPTOMATIC A. Inhibitori de cholinesteraza ( AchEI ) - DONEPEZIL - RIVASTIGMINE - GALANTAMINE
B. Antagonisti partiali de receptori NMDA ( pt. glutamat ) - MEMANTINE
C. Terapii in dezvoltare TULBURAREA COGNITIVA VASCULARA ( VCI ) BCV = a 2-a cauza a dementelor
25% dintre supravietuitorii unui prim AVC dezvolta o forma de dementa la 5 ani dupa evenimentul acut
Factorii de risc comuni pentru DA si VaD
BCV detectabila si tratabila ! MECANISME : 1. Boala de vase mari ( trombotic, tromboembolic )
2. Boala de vase mici - HTA * tip I: ischemie / edem * tip II: lacune - alte microangiopatii (inflamatorii, DZ, CAA )
3. Alte arteriopatii specifice
4. Hemodinamic
5. Embolii la distanta ( cord, aorta )
6. Hemoragii
7. Factori hematologici
8. Boli hereditare ( CADASIL, etc. )
SUBTIPURI de DEMENTE VASCULARE:
1. INFARCTE TERITORIALE MULTIPLE ( MID )
2. INFARCT UNIC STRATEGIC
3. DEMENTA VASCULARA SUBCORTICALA
- INFARCTE LACUNARE MULTIPLE
- LEZIUNI DIFUZE ALE SUBSTANTEI ALBE
4. POST- HEMORAGIE CEREBRALA
5. LEZIUNI VASCULARE MIXTE (cortico-subcorticale) Pathophysiology of dementia with CVD Dementia Final common pathway Damage to critical cortical and subcortical structures Damage/interruption of subcortical circuits and projections + Cholinergic transmission Cardiovascular risk factors Hypertension Diabetes Smoking Hypercholesterolemia Heart disease Genetics Damage to cerebral blood supply (common denominator)
Large-vessel infarcts Small-vessel infarcts Hemorrhage Hypoperfusion Multiple distinct pathophysiologies Hyperintensities (HI) Affecting ACh WM Tracts External Capsule HI Extensive Periventricular HI Deep White HI Selden NR, et al. Brain. 1998;121:2249-2257 Cortical vs Subcortical Dementias Characteristics Subcortical Dementia Cortical Dementia Executive function Very affected Consistent with other impairments Speed of cognitive processing Early slowing Normal until late Language No aphasia Early aphasia Memory Impaired recall Retrieval>recognition Recall and recognition impaired Attention Impaired Impaired Visuospatial skills Impaired Impaired Calculation Preserved until late Involved early Personality and mood Apathetic, inert, depressed, crying/laughing spells Unconcerned, euthymic Speech Dysarthric Articulate until late Coordination and gait Impaired Normal until late Motor speed and control Slowed Normal Abordarea noua a VaD si B.A.
VaD BA cu/BCV BCV este patologia; VaD is boala clinica VaD fara patologie de BA este relativ rara Multi pacienti au suprapunere de BA si BCV semnificativa Aceasta suprapunere este BA cu BCV ( AD w/CVD ) BA Management of VaD Identify patients at risk of VCI due to CVD Control vascular risk factors and disease Targeted dementia therapy Stabilization of CVD Improvement in dementia symptoms modificat dupa Sachdev et al. 1999; Nyhenuis and Gorelick, 1998 Identify patients with VCI Control of concomitent conditions Improvement in patients outcomes and caregiver QoL Dementia (DSM IV) With stroke Without stroke Total
Severe cognitive decline (MMSE) With stroke Without stroke Total Events active placebo Favours active Favours placebo Risk reduction (95%CI)
43 150 193
48 228 276
65 152 217
86 248 334
34% (3 to 55%) 1% (-24 to 22%) 12% (-8 to 28%)
45% (21 to 61%) 9% (-10 to 84%) 19% (4 to 32%) 0.5 2.0 Odds ratio 1.0 Dementia and severe cognitive decline PREVENTIA PRIMARA PREVENTIA SECUNDARA DEMENTELE FRONTO-TEMPORALE Progresele in epidemiologie, neuroimagistica, neuropatologie, genetica moleculara
Clasificari traditionale 1. Sindroame fara implicatii biologice specifice - AFAZIA PROGRESIVA - DEMENTA SEMANTICA - DEMENTA DE TIP FRONTAL 2. Entitati neuropatologice specifice - B. PICK - TAUPATIA FAMILIALA 3. Entitati familiale - FTD cu PARKINSONISM LEGATA DE CRZ. 17
* Clinic, neuropatologic, genetic: - GRUP HETEROGEN DE AFECTIUNI NEURODEGENERATIVE DEMENTELE FRONTO-TEMPORALE Se prefera CLASIFICAREA BAZATA PE PREZENTAREA CLINICA:
DEMENTA FRONTO-TEMPORALA COMPORTAMENTAL A CU TULBURARE DE LIMBAJ bv-FTD SD PNFA Kippo CM, Hodges J R, 2007 FORME CLINICE ale DFT DFT varianta COMPORTAMENTALA ( bvDFT ) 3 componente majore ( apar impreuna sau separat ):
1. Debut insidios, nespecific: ( intre decada a 3-a a 6-a de varsta ) - disfunctie executiva - alterarea judecatii, rigiditate mentala - memoria de lucru mai afectata decat memoria episodica ( de BA ) - lipsa de alterare a functiei vizuo- spatiale ( de BA ) - alterarea introspectiei - apatie si dezinteres ( confuzie cu depresia ) - hipoprosexie, distractibilitate - indecizie - impulsivitate si distractibilitate
NB. Un scor MMSE ridicat nu exclude FTD !!!!!! ( hiperoralitate +hipersexualitate +comportament de utilizare : sd. Kluver-Bucy )
2. Dezinhibitie ( valoare dg. )
: psihoza maniacala, tulb. obsesiv-compulsiva, tulb. sociopatica de personalitate - comportament infantil, grosolan - pierderea capacitatii empatice - remarci inadecvate cu tema sexuala - nerabdare - conducere auto neglijenta - cheltuieli excesive, colectionare de diverse obiecte - glume inadecvate - perseverare in activitati de rutina - hoinareala compulsiva - aport alimentar nestapanit - neglijarea igienei personale - pierderea interesului pt. familie
FORME CLINICE ale DFT DFT varianta COMPORTAMENTALA ( bvDFT ) 3 componente majore ( apar impreuna sau separat ):
3. Modificarea structurii de personalitate ( sesizata de familie / anturaj ): - furtisaguri - furturi din magazine - injuraturi - dezbracare in public - urinare frecventa - incontinenta fecala rapid progresiva
Adesea se asociaza si afazie progresiva ( valoare dg. )
Tartaglia MC, Rosen HJ , Miller BL - Neurotherapeutics: The J ournal of the American Society for Experimental Neurotherapeutics 2011; 8: 82 - 92 Top row: Sagittal view of a patient with the behavioral variant of frontotemporal dementia (bvFTD); note the anterior atrophy with relative sparing of the parietal and occipital regions. The anterior corpus callosum is also thinned compared to posterior. Coronal view of patient with semantic dementia showing significant left temporal atrophy. Coronal view of patient with nonfluent variant of FTD showing significant left insular atrophy.
Bottom row: VBM study showing that in patients with bvFTD, frontal lobe volumes are reduced compared with age-matched controls. There is volume loss in the ventromedial frontal cortex, the posterior orbital frontal regions, the insula, and the anterior cingulate cortex. DEGENERESCENTA CORTICO-BAZALA si PARALIZIA SUPRANUCLEARA PROGRESIVA Dementa Pick ( anii 30 ): asociaza semne extrapiramidale ! degenerescenta cortico-dentato-nigrala: aceeasi patologie cu b. Pick ! degenerescenta cortico-bazala ( grupul de boli Mov. Dis ) TABLOU CLINIC: 1. CBD rigiditate unilaterala + apraxie evidenta, paralizia privirii, mioclonus reflex, sd. de mana straina - pot asocia afazie primara progresiva / alte variante de FTD
2. PSP - sd. extrapiramidal simetric: distonie axiala, bradikinezie, caderi frecvente, disfagie, paralizia de verticalitate a privirii - adesea asociata cu CBD ( cu paralizie de verticalitate a privirii ) - poate preceda sau succeda tabloului clinic de FTD sau/ si PPA ( au acelasi substrat patologic ) BOALA NEURONULUI MOTOR si FTD asociere frecventa: DEMENTA + SLA ( MND ) - cca. 50% din cazurile de SLA orice forma clinica de SLA dar VARI ANTA BULBARA mai frecvent ! uneori se observa aspect tipic de bvFTD sau PPA 10% cazurile de bvFTD sau PPA dezvolta SLA substrat comun in majoritatea cazurilor: incluzii ubiquitin-pozitive, tau-negative in cortex ( descrise initial in SLA ! )
anomalii ale proteinei TDP-43 ( in SLA si varianta ubiquinata a FTD: FTLD-U )
CONCLUZII PRACTICE: * Orice pacient cu SLA trebuie evaluat cognitiv si comportamental ( clinic si neuropsihologic )
* Orice pacient cu FTD trebuie evaluat neuromuscular ( clinic si electrofiziologic ) CLASIFICAREA NEUROPATOLOGICA ACTUALA Bazata pe constituentul proteic al incluziilor neuronale si/ sau gliale: * proteina TAU : FTDL-tau
* TDP-43 ( TAR DNA-binding protein of 43 kD ): FTDL-TDP Subtipuri: - FTDL-TDP tip 1: incluzii citoplasmatice neuronale, neurite distrofice scurte in cortexul superficial - FTDL-TDP tip 2: neurite distrofice lungi in cortexul superficial si profund - FTDL-TDP tip 3: predominanta incluziilor citoplasmatice neuronale si saracie in neurite distrofice - FTDL-TDP tip 4: frecvente incluzii, asociata cu mutatii ale genei pentru valosina ( proteina )
* FUS (fused in sarcoma): FTDL - FUS Modificari comune ale acestor proteine: fosforilare anormala, ubiquitinare anormala, clivaj proteic FTLD si SLA au mecanism comun patogenic in relatie cu proteinele TDP-43 si FUS Clinical, genetic and pathological spectrum of frontotemporal lobar degeneration. Seelaar H et al. J Neurol Neurosurg Psychiatry 2011;82:476-486 Categorii de complicatii neurologice la pacientii imfectati HIV Primare mai frecvente tulburarile neurocognitive [ minore+deficit motor (MCMD) dementa asociata HIV (HAD)] mielopatia vacuolara neuropatii periferice
alte manifestari neurologice (mai frecvente la infectatii HIV vs. neinfectati, dar nu neaparat direct cauzate de HIV) neuropatii de incarcerare cefalee crize epileptice AVC miopatii Secundare imunosupresiei encefalita cu toxoplasma meningita criptococcozica encefalita cu CMV radiculita cu CMV limfomul primar SNC LEMP neurotuberculoza
Asociate cu tratamentul neuropatii toxice sd. metabolic & consecintele vasculare si neurodegenerative modificarea clinica a tulb. neurocognitive Afectarea SNC Sindroamele neurocognitive
evolutie clinica progresiva HAD este o forma definitorie de SIDA debut: de obicei cand nr. cel.T CD4+ scade sub < 200/L HAART HAD poate apare si la CD4+ > 200/L HAD prognostic prost de supravietuire cu/ fara HAART
asocierea infectiei cu HCV poate agrava disfunctia neurocognitiva mai ales disfunctia executiva AAN (American Academy of Neurology) AAN criteria defined 2 levels of neurologic manifestations of HIV infection: - HIV-associated dementia (HAD) - Minor cognitive motor disorder (MCMD)
AAN criteria for HAD were: 1) an acquired abnormality in at least two cognitive (nonmotor) areas causing impairment in work or activities of daily living (ADLs) and 2) either an abnormality of motor function or specified neuropsychiatric or psychosocial functions (e.g., motivation, emotional control, social behavior).
J anssen RS et al Nomenclature and research case definitions for neurological manifestations of human immunodeficiency virus type-1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991;41:778785.
HAD (HIV-associated dementia) defined by AAN AAN diagnostic scheme defined 3 subtypes of HAD:
1) HAD with motor symptoms (criterion 1 met fully, but only motor symptoms meeting criterion 2)
2) HAD with behavioural or psychosocial symptoms (criterion 1 met fully,but only behavioral symptoms meeting criterion 2)
3) HAD with both motor and behavioral/psychosocial symptoms (criteria 1 and 2 met fully)
Antinori A. et al, Neurology 2007, 69 (18 ): 1789-1799 A limitation of the existing AAN criteria is that they do not recognize a subgroup of HIV-infected patients (<15%) who actually have neurocognitive impairment despite the absence of overt functional decline in ADLs
There have been substantial changes to HIV disease with the introduction of HAART which have affected cognitive impairment in a number of areas
In 2007, the National Institute of Mental Health and the National Institute of Neurological Diseases and Stroke ( NINDS ) have charged a working group to critically review the adequacy and utility of these definitional criteria and to identify aspects that require updating
Antinori A. et al, Neurology 2007, 69 (18 ): 1789-1799 The three conditions comprising
HAND ( HIV Associated Neurocognitive Disorders ): ANI ( Asymptomatic Neurocognitive Impairment ) The recognition of ANI might promote the initiation of antiretroviral therapy, independent of CD4 count or plasma HIV RNA levels. These issues / questions are unresolved and require future study
may be classified using a variety of specific clinical and laboratory-based methods Caracteristici clinice ale HAD ( de obicei precedate de tulburari minore cognitive si motorii ) Declin neurocognitiv
Tulburari afectiv-comportamentale
Tulburari motorii progresive
FACTORI DE RISC: Nr. scazut de cel.CD4+ & incarcare virala plasmatica mare Anemie Toxicomanii ( cu droguri i.v. ) progresie rapida Varste extreme: varstnici & copii Incarcare virala crescuta in LCR
Tulburari cognitive acuze subiective de lentoare mentala progresiva tulburari mnestice initial minore declin mnestic progresiv hipoprosexie ( f. adesea in HAD ) pierderea capacitatii de concentrare pt. activitati cotidiene uzuale ( citit, TV, s.a. ) tulburari vizuo-spatiale discoordonare vizuo-motorie NB: MMSE nu este util in stad. incipiente ( manifestari de tip frontal )
Tulburari comportamentale apatie marcata si retragere sociala fara depresie iritabilitate marcata inflexibilitate mentala accentuata scaderea libidou-lui manifestari psihotice maniacale ( nu sunt comune )
Tulburari motorii scadere globala a fortei musculare tulburari de echilibru mers nesigur bradikinezie, parkinsonism motor semne de sd. bipiramidal miscari sacadice de urmarire ale globilor oculari semne de eliberare frontala ( stadii avansate ) mioclonii ( stadii avansate )
Diagnosis CHARTER Neurocognitive Test Battery Verbal Fluency Letter Fluency Category Fluency
Speed of Information Proc. WAIS-III Symbol Search WAIS-III Digit Symbol Trail Making Test Part A
Attention/Working Memory Paced Auditory Serial Addition Test - 50 WAIS-III Letter-Number Sequencing Motor Grooved Pegboard
Abstraction/Executive Wisconsin Card Sorting Test 64 Trail Making Test Part B
Learning and Memory Hopkins Verbal Learning Test-R Brief Visuospatial Memory Test-R Story Memory Test Figure Memory Test Everyday Functioning: Patients Assessment of Own Functioning Inventory Activities of Daily Living Scale scale International HIV Dementia Scale
Naming four objects
Fingertapping
Luria psychomotor learning task
Recall of names Sacktor et al. - Neurology 2003 60;1:A186-187